DIRS.INFO The most relevant business & tech news

☆ How breakups impact shareholders, market vs. limit orders — we've got answers
▼ + stars: | 2023-09-10 | by ( Zev Fima | ) www.cnbc.com time to read: +5 min

Hang tight: You will receive BLCO shares — eventually. A carve-out occurs when a company sells shares in the separated unit into the open market via an initial public offering (IPO). A spin-off is when management distributes shares of the new company to exiting shareholders via a special dividend. A split-off gives existing shareholders the option to receive shares in the new entity in exchange for shares in the parent company. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer, — Ted Great, Ted, Hang, Bausch, BHC, it's, Johnson, JNJ, Jim, Brendan Mcdermid Organizations: —, Bausch Health, General Electric, GE, GE HealthCare, GE Verona, CNBC, Kenvue Inc, Johnson, New York Stock Exchange Locations: BLCO, JNJ, New York City, U.S

☆ J&J to hold 9.5% stake in Kenvue after share exchange offer
▼ + stars: | 2023-08-21 | by ( ) www.reuters.com time to read: 1 min

The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsAug 21 (Reuters) - Johnson & Johnson (JNJ.N) said on Monday it was expecting to retain a stake of about 9.5% in its newly separated consumer health unit, Kenvue (KVUE.N), after completing a share exchange offer. Shares of the consumer health company rose 1.4% in premarket trading. ‍J&J launched the exchange offer last month under which its stockholders could opt for shares of the former consumer health unit related to the spinoff. Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Johnson, ‍, J, Bhanvi Satija, Mariam Sunny, Anil D'Silva Organizations: Kenvue Inc, Johnson, New York Stock Exchange, REUTERS, Thomson Locations: New York City, U.S, Bengaluru

☆ Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name health and personal care products, Kenvue CEO Thibaut Mongon said. Kenvue also noted that "private label" penetration in the consumer health product market was stable for the quarter. Those spending trends could bode well not only for Kenvue, but also for other companies in the consumer health, beauty and beverage spaces that may not see consumers trade down to cheaper products as often despite stubbornly high prices. RBC Capital analyst Nik Modi expressed confidence in Kenvue's ability to "maintain its momentum," highlighting consumer trust in the company's brands and health and personal care products overall. Meanwhile, Kenvue has gained market share, and could potentially continue to do so despite the broader environment, he noted.

Persons: Thibaut Mongon, Johnson, Mongon, Kenvue, bode, we've, Nik Modi, Modi Organizations: Kenvue Inc, New York Stock Exchange, CNBC, Johnson, J, RBC Capital Locations: Kenvue

☆ J&J-spinoff Kenvue forecasts upbeat annual profit on strong self-care demand
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +2 min

Companies Kenvue Inc FollowNeutrogena Corporation FollowHaleon Plc Follow Show more companiesJuly 20 (Reuters) - Kenvue (KVUE.N), the former consumer health unit of Johnson & Johnson (JNJ.N), forecast full-year profit above Wall Street estimates on Thursday, betting on resilient demand for its skincare and self-care products such as Neutrogena and Tylenol. Kenvue, in its first results after being spun off from Johnson & Johnson in May, forecast full-year adjusted profit per share between $1.26 and $1.31. However, adjusted gross profit margin came in at 57.5%, compared to 59.3% a year earlier, dragged by a strong dollar and higher costs. Meanwhile, J&J raised its 2023 profit forecast on Thursday, banking on the strength in its medical devices business and demand for its cancer drugs such as Darzalex. Net sales rose 5.4% to $4.01 billion while adjusted profit per share came in at 32 cents.

Persons: Johnson, Haleon, J, Ananya Mariam Rajesh, Raghav, Devika Syamnath Organizations: Johnson, Wall, Thomson Locations: Bengaluru

☆ Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue , which spun out as an independent consumer health company just two months ago. That process, also known as a split-off, will allow J&J shareholders to exchange all or a portion of their shares for Kenvue's common stock. Kenvue shares fell following the announcement Thursday, even though the company beat earnings and revenue estimates in its first quarterly report since its IPO. Previously, J&J did not disclose whether it would divest its Kenvue shares through a split-off or a spinoff. The latter would involve distributing Kenvue stock to existing J&J shareholders rather than giving them the option to exchange.

Persons: Thibaut Mongon, Paul Ruh, Johnson, J, Joseph Wolk, Wolk, J's, CNBC's, Kenvue, Goldman Sachs, JPMorgan Chase Organizations: Kenvue Inc, New York Stock Exchange, JPMorgan Locations: New York City, U.S

Rubrik may raise more than $750 million in its IPO, three of the sources added, though that may change based on market conditions as the preparations are still at an early stage. Rubrik currently generates annual recurring revenue of about $600 million, one of the sources said. Three of the sources said Rubrik could choose to go public in 2024, if the IPO market becomes more welcoming. Founded in 2014 by venture capitalist Bipul Sinha, Rubrik makes cloud-based ransomware protection and data-backup software. SoftBank-backed Cohesity Inc, which competes with Rubrik, is also preparing to go public, having filed confidentially for an IPO in late 2021, Reuters reported.

Persons: Goldman Sachs, Rubrik, Bipul Sinha, Johnson, Echo Wang, Milana Vinn, Krystal Hu, Matthew Lewis Organizations: YORK, Microsoft Corp, Barclays Plc, Citigroup Inc, Barclays, Citi, Nvidia Corp, Depot Inc, Bain Capital Ventures, Lightspeed Venture Partners, Kenvue Inc, Johnson, SoftBank Group Corp, Inc, Reuters, Cohesity Inc, Thomson Locations: U.S, Palo Alto , California, ., New York

☆ Biopharma firm Acelyrin valued at $2.1 billion in strong market debut
▼ + stars: | 2023-05-05 | by ( ) www.reuters.com time to read: +1 min

May 5 (Reuters) - Shares of Acelyrin Inc (SLRN.O) rose 28% in their Nasdaq debut on Friday, giving the biopharma company a market capitalization of $2.1 billion. The Los Angeles-based company, which had priced its shares at $18 apiece, raised $540 million by selling 30 million shares in an upsized offering on Thursday. Acelyrin joins a spate of new listings recently that have fueled hopes of a recovery in IPO markets. On Thursday, Johnson & Johnson Inc's (JNJ.N) consumer health business Kenvue Inc (KVUE.N) went public, becoming the largest public offering since Rivian Automotive Inc (RIVN.O) in 2021. Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.

☆ Kenvue CEO looks to brand, product innovation to drive growth after IPO
▼ + stars: | 2023-05-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company's IPO at the New York Stock Exchange (NYSE), May 4, 2023. Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out company after its solid debut on the public market Thursday. Kenvue, spun out of Johnson & Johnson , carries a packed portfolio of widely known brands, such as Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno and J&J's namesake baby powder. But Mongon told CNBC that Kenvue's portfolio of brands has "ample opportunity" to grow. Mongon believes product innovation ultimately makes Kenvue's brands "more relevant than ever" to consumers as they better target their needs.

☆ Johnson & Johnson's consumer health unit Kenvue started trading. What it means for J&J shareholders like us
▼ + stars: | 2023-05-05 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +9 min

For now, it's not exactly clear how J & J will go about the second step of this divestiture. In this scenario, we would have the option to relinquish some, all or none of our J & J shares. In fact, our optimism around the breakup was a big reason we bought into J & J nearly a year ago . J & J continues to argue against claims that its baby powder and other talc products caused cancer lack merit. "Look at it as a whole company today, knowing that [roughly] 10% doesn't belong to J & J," explained Cantor Fitzgerald analyst Louise Chen, who has a buy rating and maintains a $215 price target on J & J.

☆ J&J's Kenvue eyes $47 billion valuation in biggest US IPO since 2021
▼ + stars: | 2023-05-04 | by ( ) www.reuters.com time to read: +1 min

[1/2] The company logo for Kenvue Inc. Johnson & Johnson's consumer-health business, is displayed on a screen during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. REUTERS/Brendan McDermidMay 4 (Reuters) - Johnson & Johnson's (JNJ.N) consumer health unit Kenvue Inc (KVUE.N) was set to fetch a valuation of about $47 billion on Thursday, in what would be the biggest U.S. initial public offering since late 2021. Shares, priced at $22 apiece by Kenvue, were indicated to open nearly 14% above their offer price on the New York Stock Exchange. While the Kenvue deal is the largest IPO to launch since electric-vehicle maker Rivian Automotive Inc (RIVN.O) listed its shares on the Nasdaq in late 2021, deal advisers have warned that equity capital markets may not recover in a meaningful way any time soon. Reporting by Manya Saini and Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
▼ + stars: | 2023-05-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson's consumer-health business, pose together during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Johnson & Johnson 's consumer health spinoff Kenvue jumped 16% in its market debut on the New York Stock Exchange Thursday, marking the biggest U.S. IPO in more than a year. Kenvue sold 172.8 million shares in an upsized deal that raised about $3.8 billion and valued the company at roughly $41 billion. "Millions of consumers around the world this morning wake up with a Kenvue product in their home," CEO Thibaut Mongon, told CNBC's "Squawk on the Street" Thursday morning ahead of the stock's debut. Mongon previously served as J&J's executive vice president and worldwide chair of consumer health.

☆ J&J's Kenvue prices IPO within range to raise $3.7 bln - source
▼ + stars: | 2023-05-03 | by ( Echo Wang | ) www.reuters.com time to read: 1 min

NEW YORK, May 3 (Reuters) - Johnson & Johnson (JNJ.N) on Wednesday priced the initial public offering (IPO) of its consumer-health business at the upper end of its target range to raise $3.66 billion, people familiar with the matter said,Kenvue Inc defied volatile market conditions to price about 166 million shares at $22 per share, the source said, requesting anonymity as these discussions are confidential. The IPO values Kenvue at about $41 billion. Kenvue had earlier said it planned to sell 151 million shares at a range of between $20 and $23 per share. read moreJ&J did not immediately respond to a request for comment. Reporting by Echo Wang in New York; Editing by Anirban SenOur Standards: The Thomson Reuters Trust Principles.

☆ J&J's Kenvue prices upsized IPO at upper end of range to raise $3.7 bln -sources
▼ + stars: | 2023-05-03 | by ( Echo Wang | ) www.reuters.com time to read: +1 min

Kenvue defied volatile market conditions to price about 166 million shares at $22 per share, the sources said, adding that the size of the deal was upsized by about 10%. The IPO values Kenvue at about $41 billion. Kenvue had earlier said it planned to sell 151 million shares at a range of between $20 and $23 per share. Kenvue's share sale marks the biggest IPO to result from a corporate carve-out in over two decades. The IPO market has been largely frozen over the past year as stock-market volatility and economic uncertainty have put off many hopefuls.

While SoftBank had said in March it planned to list Arm in the U.S. stock market, the company's IPO registration shows that it is pressing ahead with the blockbuster offering despite adverse market conditions. Arm plans to sell its shares on Nasdaq later this year, seeking to raise between $8 billion and $10 billion, the sources said. SoftBank and Arm declined to comment. There are signs that the IPO market is beginning to thaw. Arm's IPO preparations are being led by Goldman Sachs Group Inc (GS.N), JPMorgan Chase & Co (JPM.N), Barclays (BARC.L) and Mizuho Financial Group (8411.T).

☆ J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market
▼ + stars: | 2023-04-23 | by ( Corrie Driebusch | Peter Loftus | ) www.wsj.com time to read: 1 min

The division slated to become Kenvue generated $14.95 billion in global sales last year, about 15.7% of Johnson & Johnson’s total. Photo: BRENDAN MCDERMID/REUTERSJohnson & Johnson is poised to begin a roadshow to pitch shares of its consumer-healthcare business, the producer of household names such as Tylenol, in a test for an IPO market that has been in the doldrums for the past year. Kenvue Inc. plans to start meeting with prospective investors as early as Monday, people familiar with the matter said. The goal is to raise $3.5 billion or more in the offering at a valuation close to $40 billion, the people said. IPO roadshows typically last anywhere from a few days to a week ahead of the stock’s trading debut.

Search resuls for: "Kenvue Inc"

15 mentions found